Company Introduction

Company introduction

Products
Product Details

SK Chemicals Co. Ltd. SKYCellflu

cell-culture based influenza vaccine in Korea and third worldwide.
Uses SK’s proprietary technology

R&D Pipeline
Since entering the vaccine industry in 2002, Pipeline Description DS PC PI PⅡ PⅢ NDA MKT
SK Chemicals has strongly focused on its Pneumococcal
vaccine R&D capability, obtaining fundamental NBP606 ○
Conjugate vaccine
proprietary technologies for developing vaccines
SKYCellflu Quadrivalent Cell-based
highly demanded around the world. Quadrivalent flu vaccine
○

In line with its R&D efforts, SK Chemicals constructed a new GMP-com- Varicella vaccine ○
pliant vaccine manufacturing facility in 2011 with cutting-edge NBP608 Herpes Zoster (Shingles)
single-use, modular production system, which allows highly efficient ○
vaccine
commercial scale production of different types of vaccines including the
company’s own vaccine. Typhoid Conjugate
SK Chemicals’ new “SKYCellflu” influenza vaccine is being manufac- NBP ○
vaccine
tured using cell-based production technology, which does not contains
antibiotics or preservatives. NBP Vaccine in development ○ ○
SK Chemicals has also entered collaboration with the IVI, the Gates
Foundation and Sanofi Pasteur for development of vaccines. In Latin
America, SK Chemicals is looking to pursue partnerships with variety of
collaboration model in consideration, ranging from transfer of technolo-
CEO
Mahnhoon Park
gy to distribution agreements.
Location
310, Pangyo-ro, Bundang-gu,
Seongnam-si, Gyeonggi-do,
13494 Republic of Korea
Homepage
www.skchemicals.com/en/
Contact
Jin Seon Park
Phone: +82-2-2008-2888
Fax: +82-2-2008-2959
Email: lifescience_global@sk.com

58 59